Faculty Bibliography
Searched for:
person:passip01
Total Results:
854
P74. Adult spinal deformity patients with metabolic syndrome have significantly higher costs [Meeting Abstract]
BACKGROUND CONTEXT: Adult spinal deformity (ASD) correction involves complex, invasive procedures. However, it is unknown how metabolic syndrome affects the cost efficiency of ASD surgery. PURPOSE: Investigate the differences in ASD surgery cost for metabolic syndrome patients. STUDY DESIGN/SETTING: Retrospective review of a single center ASD database. PATIENT SAMPLE: A total of 557 ASD patients. OUTCOME MEASURES: Complications, revisions and costs.
METHOD(S): ASD patients (scoliosis >=20degree, SVA>=5cm, PT >=25degree, or TK >=60degree) >=18, undergoing >=4 level fusions were included. Descriptive analysis assessed mean baseline demographic, radiographic and surgical data were assessed. Patients diagnosed with: BMI >30, diabetes mellitus, and HTN were classified metabolic syndrome patients (MetS). Independent samples T-tests assessed baseline differences in SVA, PT, PI-LL, and levels fused between MetS and non-MetS patients. Total surgery costs for MetS and non-MetS ASD patients were compared. Costs were calculated using the PearlDiver database, which reflects both private insurance and Medicare reimbursement claims. Complications and comorbidities (CC) and major complications and comorbidities (MCC) were assessed according to CMS.gov manual definitions.
RESULT(S): A total of 557 patients met inclusion criteria. Baseline demographics and surgical details: age 60.8 +/- 13.2, 67.5% female, BMI 28.3 +/- 6.67, 6.2% anterior approach, 81.0% posterior approach, 12.8% combined approach, 10.4 +/- 3.9 levels fused, op time 423.5 +/- 166.4 minutes, EBL 2061.4 +/- 1631.5 cc, LOS 7.6 +/- 5.4 days. 11 MetS patients were included. There was no significant difference in BL SVA (54.2degree vs 70.3degree), PT (26.7degree vs 23.7degree), PI-LL (16.4degree vs 21.2degree), or levels fused between groups (10.5 vs 10.6) (all p>0.05). Twenty-seven percent of MetS patients experienced a CC or MCC, with 18% undergoing revisions within 90 days (vs 13.2% and 3.2% for non-MetS, p<0.05). The average costs of surgery for MetS patients was $68,004.06 vs $48,726.40 for non-MetS patients (p<0.05).
CONCLUSION(S): Metabolic syndrome is a growing concern among health care providers. In metabolic syndrome patients undergoing corrective adult spinal deformity surgery, the total costs of surgery was 28.4% higher for metabolic syndrome patients ($68,004.06 vs $48,726.40). Optimizing modifiable factors like diabetes or BMI in preoperative patients may have an impact on cost effectiveness. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): ASD patients (scoliosis >=20degree, SVA>=5cm, PT >=25degree, or TK >=60degree) >=18, undergoing >=4 level fusions were included. Descriptive analysis assessed mean baseline demographic, radiographic and surgical data were assessed. Patients diagnosed with: BMI >30, diabetes mellitus, and HTN were classified metabolic syndrome patients (MetS). Independent samples T-tests assessed baseline differences in SVA, PT, PI-LL, and levels fused between MetS and non-MetS patients. Total surgery costs for MetS and non-MetS ASD patients were compared. Costs were calculated using the PearlDiver database, which reflects both private insurance and Medicare reimbursement claims. Complications and comorbidities (CC) and major complications and comorbidities (MCC) were assessed according to CMS.gov manual definitions.
RESULT(S): A total of 557 patients met inclusion criteria. Baseline demographics and surgical details: age 60.8 +/- 13.2, 67.5% female, BMI 28.3 +/- 6.67, 6.2% anterior approach, 81.0% posterior approach, 12.8% combined approach, 10.4 +/- 3.9 levels fused, op time 423.5 +/- 166.4 minutes, EBL 2061.4 +/- 1631.5 cc, LOS 7.6 +/- 5.4 days. 11 MetS patients were included. There was no significant difference in BL SVA (54.2degree vs 70.3degree), PT (26.7degree vs 23.7degree), PI-LL (16.4degree vs 21.2degree), or levels fused between groups (10.5 vs 10.6) (all p>0.05). Twenty-seven percent of MetS patients experienced a CC or MCC, with 18% undergoing revisions within 90 days (vs 13.2% and 3.2% for non-MetS, p<0.05). The average costs of surgery for MetS patients was $68,004.06 vs $48,726.40 for non-MetS patients (p<0.05).
CONCLUSION(S): Metabolic syndrome is a growing concern among health care providers. In metabolic syndrome patients undergoing corrective adult spinal deformity surgery, the total costs of surgery was 28.4% higher for metabolic syndrome patients ($68,004.06 vs $48,726.40). Optimizing modifiable factors like diabetes or BMI in preoperative patients may have an impact on cost effectiveness. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747218
ISSN: 1878-1632
CID: 4597582
28. Does baseline thoracolumbar shape influence patterns of cervical decompensation following surgical adult spinal deformity correction? [Meeting Abstract]
BACKGROUND CONTEXT: Adult spinal deformity (ASD) surgery is complex and may lead to new-onset cervical malalignment and/or proximal junctional kyphosis (PJK). Roussouly et al describes variations in baseline thoracolumbar (TL) shape (Types 1-4), which have been shown to differentially influence surgical ASD outcomes. The effect of morphological shape on patterns of postoperative CD development remains underexplored. PURPOSE: Stratify patients by Roussouly type and assess patterns of conversion from baseline (BL) cervical alignment to postoperative cervical deformity (CD) in patients undergoing thoracolumbar ASD surgery. STUDY DESIGN/SETTING: Retrospective review of a prospective multicenter database of ASD patients. PATIENT SAMPLE: A total of 266 surgical ASD patients. OUTCOME MEASURES: Rate and timing of conversion to CD, rate of PJK, radiographic alignment parameters.
METHOD(S): Operative ASD patients with complete radiographic data at baseline, 6W, 1Y, 2Y, & 3Y intervals were included. Patients were grouped by baseline PI and apex of LL into component types of the Roussouly classification system utilizing pelvic incidence as published by Pizones et al. Patients with no BL CD were postoperatively stratified by Ames CD criteria (TS-CL>20 degree, cSVA>40mm), where CD was defined as fulfilling >1 criteria. Follow-up intervals were established post-ASD surgery, with 6W postop defined as "Early," 6W-1Y "Intermediate," 1-2Y "Late," and 2-3Y "Long." Univariate and Cox regression analyses identified CD conversion rate and PJK rate (<-10degree change in UIV and UIV+2) across Roussouly types 1-4.
RESULT(S): A total of 266 surgical ASD patients (59.7yrs, 77.4% F) with complete radiographic data were included. By Roussouly classification, 9% were Type 1, 15.8% Type 2, 46.6% Type 3, and 28.6% Type 4. 28.6% of ASD patients converted to postop CD (Early: 14.3%, Intermediate: 5.3%, Late: 4.1%, Long: 4.9%). There were no significant differences in CD conversion rate across Roussouly types (1: 33.3%; 2: 28.6%; 3: 26.6%; 4: 30.3%, P=0.895). Types 2 (41.7%), 3 (60.6%), and 4 (43.5%) had their peak rates of conversion in the Early (<6w) window compared to other follow-up intervals, whereas Type 1 patients had a peak rate (50%) between 6w-1Y. Type 2 patients had higher rates of later CD conversion (>1 year) than other types (50% vs 28.1%, P=0.135), while Type 1 patients trended higher rates of earlier CD conversion (<1 year) than other types (33.8% vs 12.5%, P=0.220); these patterns did not reach statistical significance. Across Roussouly Types, among patients who converted to CD, Type 4 had significantly higher rates of ++ SRS-Schwab PT and greater TPA at BL (both p<0.05). Type 4 patients had the highest rate of concurrent PJK with CD conversion (60.9%) compared to Type 1 (50%), Type 2 (50%), or Type 3 (54.5%) (P>0.05). There were no significant change in ODI, PCS, or SRS total among Roussouly Types in patients that converted to CD (p>0.05). Random forest analysis determined the top surgical (levels fused), radiographic (TS-CL), and demographic (frailty) factors associated with CD conversion.
CONCLUSION(S): Baseline thoracolumbar shape as described by the Roussouly classification has a differential effect on timing to CD conversion, though overall rates of CD conversion after TL-ASD correction were similar across Types 1-4. Type 1 patients with a lower apex of lumbar lordosis trended earlier conversion, while Type 2 patients with a higher apex of LL trended conversion beyond 1-year postop. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): Operative ASD patients with complete radiographic data at baseline, 6W, 1Y, 2Y, & 3Y intervals were included. Patients were grouped by baseline PI and apex of LL into component types of the Roussouly classification system utilizing pelvic incidence as published by Pizones et al. Patients with no BL CD were postoperatively stratified by Ames CD criteria (TS-CL>20 degree, cSVA>40mm), where CD was defined as fulfilling >1 criteria. Follow-up intervals were established post-ASD surgery, with 6W postop defined as "Early," 6W-1Y "Intermediate," 1-2Y "Late," and 2-3Y "Long." Univariate and Cox regression analyses identified CD conversion rate and PJK rate (<-10degree change in UIV and UIV+2) across Roussouly types 1-4.
RESULT(S): A total of 266 surgical ASD patients (59.7yrs, 77.4% F) with complete radiographic data were included. By Roussouly classification, 9% were Type 1, 15.8% Type 2, 46.6% Type 3, and 28.6% Type 4. 28.6% of ASD patients converted to postop CD (Early: 14.3%, Intermediate: 5.3%, Late: 4.1%, Long: 4.9%). There were no significant differences in CD conversion rate across Roussouly types (1: 33.3%; 2: 28.6%; 3: 26.6%; 4: 30.3%, P=0.895). Types 2 (41.7%), 3 (60.6%), and 4 (43.5%) had their peak rates of conversion in the Early (<6w) window compared to other follow-up intervals, whereas Type 1 patients had a peak rate (50%) between 6w-1Y. Type 2 patients had higher rates of later CD conversion (>1 year) than other types (50% vs 28.1%, P=0.135), while Type 1 patients trended higher rates of earlier CD conversion (<1 year) than other types (33.8% vs 12.5%, P=0.220); these patterns did not reach statistical significance. Across Roussouly Types, among patients who converted to CD, Type 4 had significantly higher rates of ++ SRS-Schwab PT and greater TPA at BL (both p<0.05). Type 4 patients had the highest rate of concurrent PJK with CD conversion (60.9%) compared to Type 1 (50%), Type 2 (50%), or Type 3 (54.5%) (P>0.05). There were no significant change in ODI, PCS, or SRS total among Roussouly Types in patients that converted to CD (p>0.05). Random forest analysis determined the top surgical (levels fused), radiographic (TS-CL), and demographic (frailty) factors associated with CD conversion.
CONCLUSION(S): Baseline thoracolumbar shape as described by the Roussouly classification has a differential effect on timing to CD conversion, though overall rates of CD conversion after TL-ASD correction were similar across Types 1-4. Type 1 patients with a lower apex of lumbar lordosis trended earlier conversion, while Type 2 patients with a higher apex of LL trended conversion beyond 1-year postop. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747230
ISSN: 1878-1632
CID: 4597572
32. Preoperative high frequency opioid use dramatically increases complication rate within 90 days, increases two-year reoperation rates, and predisposes to opioid dependency following adult spinal deformity correction [Meeting Abstract]
BACKGROUND CONTEXT: With a heightened focus on prescription narcotic use in the United States, concern among surgeons has increased regarding preoperative and postoperative usage. However, the literature is scarce on outcomes of preoperative and prolonged opioid usage in adult spinal deformity (ASD) patients. PURPOSE: Investigate effect of preoperative opioid usage on prolonged opioid use postoperatively and rates of reoperations. STUDY DESIGN/SETTING: Retrospective review of the PearlDiver Database 2008-2013. PATIENT SAMPLE: A total of 7,661 ASD patients. OUTCOME MEASURES: Reoperations, 90-day complications, comorbidity burden, prolonged opioid usage METHODS: ASD patients undergoing a fusion were isolated in the PearlDiver database between the years 2008-2013 using ICD-9 and CPT codes. Patients were stratified by prescription preoperative opioid use 3 months prior to surgery: (1) high frequency (>4 refills); (2) low frequency (1-3 refills); (3) opioid naive. Means comparison tests compared differences in demographics, complications, and reoperation rates. Logistic regression assessed the odds of complication and reoperations associated with preoperative frequency and prolonged opioid use (3 to 6 months postop), controlling for age, sex, and comorbidities.
RESULT(S): A total of 7,661 ASD patients were isolated; 2,342 patients were high frequency preop opioid users, 2,247 low frequency preop opioid users, and 3,072 opioid naive. At BL, high frequency preop opioid users had higher rates of obesity, diabetes mellitus, CHF, COPD, hypertension, smoking and alcohol use (all p<0.001). Compared to opioid naive patients, low frequency preop opioid users had higher rates of 90-day complications associated with hematoma and transfusion (p<0.05). High frequency preop opioid users relative to naive opioid users had significantly increased 90-day complication rates including pulmonary embolism, pneumonia, hematoma, and transfusions. High frequency opioid use was associated with increased odds of wound disruption (1.74[1.22-2.51]) and hospital readmission (1.42[1.22-1.64], both p<0.05). Additionally, high frequency opioid usage preop followed by prolonged opioid use postop was associated with increased odds of reoperations at 2Y relative to low frequency (1.67[1.34-2.10]) and opioid naive patients (1.83[1.40-2.42], both p<0.001).
CONCLUSION(S): Patients with high frequency preoperative opioid use are at increased risk of major complications within 90 days of surgery, prolonged use postoperatively, and increased risk of reoperations within two years. During preoperative risk assessment, providers should consider the effect of pre- and postoperative opioid usage on patient outcomes. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
RESULT(S): A total of 7,661 ASD patients were isolated; 2,342 patients were high frequency preop opioid users, 2,247 low frequency preop opioid users, and 3,072 opioid naive. At BL, high frequency preop opioid users had higher rates of obesity, diabetes mellitus, CHF, COPD, hypertension, smoking and alcohol use (all p<0.001). Compared to opioid naive patients, low frequency preop opioid users had higher rates of 90-day complications associated with hematoma and transfusion (p<0.05). High frequency preop opioid users relative to naive opioid users had significantly increased 90-day complication rates including pulmonary embolism, pneumonia, hematoma, and transfusions. High frequency opioid use was associated with increased odds of wound disruption (1.74[1.22-2.51]) and hospital readmission (1.42[1.22-1.64], both p<0.05). Additionally, high frequency opioid usage preop followed by prolonged opioid use postop was associated with increased odds of reoperations at 2Y relative to low frequency (1.67[1.34-2.10]) and opioid naive patients (1.83[1.40-2.42], both p<0.001).
CONCLUSION(S): Patients with high frequency preoperative opioid use are at increased risk of major complications within 90 days of surgery, prolonged use postoperatively, and increased risk of reoperations within two years. During preoperative risk assessment, providers should consider the effect of pre- and postoperative opioid usage on patient outcomes. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747494
ISSN: 1878-1632
CID: 4597062
289. Risk of spinal surgery among individuals who have been revascularized for coronary artery disease [Meeting Abstract]
BACKGROUND CONTEXT: For patients with coronary artery disease, the two most common options for intervention are a cardiac stent or a coronary artery bypass graft. Although less invasive, stents may pose a long-term risk for patients undergoing further invasive procedures such as elective spine surgery. This study aimed to provide surgeons with insight on possible major complications for elective spine surgery patients with a history of coronary artery disease. PURPOSE: Investigate outcomes of elective spine fusion patients with prior history of cardiac intervention STUDY DESIGN/SETTING: Retrospective review of the PearlDiver database between the years 2006-2013 PATIENT SAMPLE: A total of 731,173 elective spine fusion patients OUTCOME MEASURES: Comorbidity burden, 30-day and 90-day complications, readmission METHODS: Elective spine fusion patients were isolated with ICD-9 and CPT procedures codes in the PearlDiver database. Patients were stratified by having previous history of a coronary stent (Stent), coronary artery bypass graft (CABG), and no previous heart procedure (No-HP). Means comparison tests (chi-squared and independent samples t-tests, as appropriate) compared differences in demographics, diagnoses, and comorbidities. Logistic regression assessed the odds of 30-day and 90-day postoperative (postop) complications associated with each heart procedure (Odds Ratio [95% confidence interval]). Statistical significance was set p<0.05.
RESULT(S): A total of 731,173 elective spine fusion patients were included. Overall, 8,401 pts underwent a CABG, 24,037 patients Stent, and 698,735 had No-HP prior to spine fusion surgery. Compared to Stent and No-HP patients, CABG patients had higher rates of morbid obesity, chronic kidney disease and diabetes (p<0.001 for all). Stent patients had higher rates of peripheral vascular disease, hypertension, and hyperlipidemia (all p<0.001). Within 30 days postoperatively of index surgery, CABG patients had significantly higher complication rates including pneumonia, cerebrovascular accident (CVA), myocardial infarction (MI), sepsis, and death compared to No-HP (all p<0.001). Stent patients vs No-HF also had higher 30-day postoperative complication rates including pneumonia, CVA, MI, sepsis, and death. Adjusting for age, comorbidities and sex, Stent was significantly predictive of a MI 30-days post-op (OR: 1.90 [1.53-2.34], P<0.001). Additionally, Stent patients compared to CABG patients had 1.99x greater odds of a MI within 30-days (OR: 1.99 [1.26-3.31], p=0.005) and 2.02x greater odds of readmission within 90-days postop (OR: 2.2 [1.53-2.71, p<0.001).
CONCLUSION(S): With regards to spine surgery, coronary artery bypass graft remains the gold standard for risk reduction. Stenting does not appear to minimize risk as significantly as CABG. When assessing patients with a history of coronary artery disease for elective spine fusion surgery, surgeons should be cautious of the significant risk of major complications associated with stents compared to coronary artery bypass grafting. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
RESULT(S): A total of 731,173 elective spine fusion patients were included. Overall, 8,401 pts underwent a CABG, 24,037 patients Stent, and 698,735 had No-HP prior to spine fusion surgery. Compared to Stent and No-HP patients, CABG patients had higher rates of morbid obesity, chronic kidney disease and diabetes (p<0.001 for all). Stent patients had higher rates of peripheral vascular disease, hypertension, and hyperlipidemia (all p<0.001). Within 30 days postoperatively of index surgery, CABG patients had significantly higher complication rates including pneumonia, cerebrovascular accident (CVA), myocardial infarction (MI), sepsis, and death compared to No-HP (all p<0.001). Stent patients vs No-HF also had higher 30-day postoperative complication rates including pneumonia, CVA, MI, sepsis, and death. Adjusting for age, comorbidities and sex, Stent was significantly predictive of a MI 30-days post-op (OR: 1.90 [1.53-2.34], P<0.001). Additionally, Stent patients compared to CABG patients had 1.99x greater odds of a MI within 30-days (OR: 1.99 [1.26-3.31], p=0.005) and 2.02x greater odds of readmission within 90-days postop (OR: 2.2 [1.53-2.71, p<0.001).
CONCLUSION(S): With regards to spine surgery, coronary artery bypass graft remains the gold standard for risk reduction. Stenting does not appear to minimize risk as significantly as CABG. When assessing patients with a history of coronary artery disease for elective spine fusion surgery, surgeons should be cautious of the significant risk of major complications associated with stents compared to coronary artery bypass grafting. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747388
ISSN: 1878-1632
CID: 4597302
178. Minimally invasive surgery mitigates but does not eliminate adverse perioperative outcomes for frail TLIF [Meeting Abstract]
BACKGROUND CONTEXT: Frailty is an increasingly recognized characteristic that has been validated across many studies as influencing operative risk. Utilization of frailty indices can allow for its identification of which spine patients may be too high risk for surgical intervention. This may be especially useful when it comes to surgeries that are minimally invasive and are supposed to have decrease perioperative outcomes. PURPOSE: Identify MIS techniques effects in postoperative outcomes in TLIF patients. STUDY DESIGN/SETTING: Retrospective review of a prospective database. PATIENT SAMPLE: TLIF spine patients. OUTCOME MEASURES: Complications, length of stay (LOS), estimated blood loss (EBL).
METHOD(S): Pts that underwent a lumbar spine procedure in a single-center Comprehensive Spine Quality Database. Pts were stratified based on procedural approach (Open [OP] and Minimally invasive Surgery [MIS]). Frailty was then calculated for each resultant group by using 30 variables with a validated method. Based on these scores, pts were categorized no frailty [NF]: <0.09, frail [F]: 0.09-0.18, and severe frailty [SF] >0.18. Groups were then controlled for surgical invasiveness. Chi-squared tests identified the relationship between complications and length of stay among various frailty states given surgical approach (OP vs MIS). These patients were propensity score matched for levels fused. Hospital acquired complications (HACs) were identified based on frailty groups through the use of chi-squared and t-tests for other surgical factors. A logistic regression analysis identified the association between frailty status and surgical, regarding postoperative (postop) outcomes.
RESULT(S): A total of 1,300 TLIF spine patients were isolated (59yrs, 29.3kg/m2). After PSM for levels fused, there were 338 pts for both MIS and OP. MIS pts were older (56.1 vs 53.3; p<0.05) than Op pts and had similar BMI's (29.1 vs 29.7; respectively). However, OP received more posterior approaches and less anterior approaches than MIS pts (p<0.05). By surgical factors: MIS and OP patients had similar LOS (3 vs 2.9days) and EBL (282.8 vs 251.5cc) but differed by Op time (195.7 vs 247.1; p<0.05) respectively. Further breakdown by frailty displayed statistical significance between MIS and OP patients with MIS pts having more F (16% vs 12%) and SF pts (4.3% vs 1.9%) than OP (all p<0.05). FMIS patients had lower postop neurologic complications as compared to FOP pts (4.63% vs 14.8%). However, SFMIS patiens had more post-operative complications than SFOP pts (55.2% vs 23.1%) and increased a pt's likelihood of being SFMIS by 5.4x's (all p<0.05).
CONCLUSION(S): This study displays that when frailty status is taken into account, TLIF MIS patients benefit from this procedure type when analyzed against neurologic complications. However, these patients were seen to suffer more from postop complications but did not differ on any other specific complications or surgical variables. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): Pts that underwent a lumbar spine procedure in a single-center Comprehensive Spine Quality Database. Pts were stratified based on procedural approach (Open [OP] and Minimally invasive Surgery [MIS]). Frailty was then calculated for each resultant group by using 30 variables with a validated method. Based on these scores, pts were categorized no frailty [NF]: <0.09, frail [F]: 0.09-0.18, and severe frailty [SF] >0.18. Groups were then controlled for surgical invasiveness. Chi-squared tests identified the relationship between complications and length of stay among various frailty states given surgical approach (OP vs MIS). These patients were propensity score matched for levels fused. Hospital acquired complications (HACs) were identified based on frailty groups through the use of chi-squared and t-tests for other surgical factors. A logistic regression analysis identified the association between frailty status and surgical, regarding postoperative (postop) outcomes.
RESULT(S): A total of 1,300 TLIF spine patients were isolated (59yrs, 29.3kg/m2). After PSM for levels fused, there were 338 pts for both MIS and OP. MIS pts were older (56.1 vs 53.3; p<0.05) than Op pts and had similar BMI's (29.1 vs 29.7; respectively). However, OP received more posterior approaches and less anterior approaches than MIS pts (p<0.05). By surgical factors: MIS and OP patients had similar LOS (3 vs 2.9days) and EBL (282.8 vs 251.5cc) but differed by Op time (195.7 vs 247.1; p<0.05) respectively. Further breakdown by frailty displayed statistical significance between MIS and OP patients with MIS pts having more F (16% vs 12%) and SF pts (4.3% vs 1.9%) than OP (all p<0.05). FMIS patients had lower postop neurologic complications as compared to FOP pts (4.63% vs 14.8%). However, SFMIS patiens had more post-operative complications than SFOP pts (55.2% vs 23.1%) and increased a pt's likelihood of being SFMIS by 5.4x's (all p<0.05).
CONCLUSION(S): This study displays that when frailty status is taken into account, TLIF MIS patients benefit from this procedure type when analyzed against neurologic complications. However, these patients were seen to suffer more from postop complications but did not differ on any other specific complications or surgical variables. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747442
ISSN: 1878-1632
CID: 4597182
293. The modified adult spinal deformity frailty index (mASD-FI) is a good preoperative risk assessment tool [Meeting Abstract]
BACKGROUND CONTEXT: To make the 40-factor adult spinal deformity frailty index (ASD-FI) more practical for use in clinical setting, a recent study proposed a modified, 8-factor frailty index (mASD-FI). The mASD-FI quantifies frailty of ASD patients on a scale from 0 to 21, with higher scores indicating greater frailty. While the mASD-FI has been shown to correlate with preoperative pain and disability, its relationship with postoperative outcomes has not been investigated. PURPOSE: Assess the relationship between mASD-FI score and clinical outcomes after ASD-corrective surgery. STUDY DESIGN/SETTING: Retrospective cohort study PATIENT SAMPLE: A total of 509 ASD patients OUTCOME MEASURES: Length of stay (LOS), complications, health-related quality of life (HRQL) questionnaires: ODI, SRS-22r, EQ-5D, SF-36 Physical Component Score (PCS).
METHOD(S): ASD patients (scoliosis>=20degree, SVA>=5cm, PT>=25degree, or TK >=60degree) with available mASD-FI scores and HRQL data at pre- and 2-years postop intervals were included. Patients were stratified by mASD-FI score using published cutoffs: not frail (<7), frail (7-12), severely frail (>12). Analysis of variance (ANOVA) assessed differences in demographics, surgical factors, and HRQL across frailty groups. Linear regression assessed the relationship between mASD-FI score and postop clinical outcomes (LOS, HRQL scores). Binary logistic regression assessed the relationship between frailty category and odds of complication or reoperation (results presented: odds ratio [95% confidence interval]).
RESULT(S): A total of 509 ASD patients were included (59+/-14yrs, 79%F, BMI: 27.7+/-6.0 kg/m2). The overall cohort presented with moderate baseline deformity: SVA (83.7mm+/-71), PT (12.7degree+/-10.8), PI-LL (43.1degree+/-21.1). Mean preop mASD-FI score was 7.2+/-5.0, and breakdown by frailty category was: not frail (50.3%), frail (34.0%), severely frail (15.7%). Preop age, BMI, and Charlson Comorbidity Index score all increased across increasing frailty categories (all p<0.001); however, fusion length (p=0.247) and rates of osteotomy (p=0.731) did not. At baseline, increasing frailty was associated with inferior ODI, EQ-5D, SRS-22r, SF-36 PCS, and NRS Back and Leg pain scores (all p<0.001). Following surgery, length of stay increased with increasing frailty category (6.9 days, 7.9 days, 9.6 days, p<0.001). Complication rates increased with frailty (57.6%, 64.4%, 78.7%, p<0.001). Increasing frailty was also associated with inferior postoperative outcomes for ODI (19.9, 31.8, 41.2), SRS (3.9, 3.6, 3.2), EQ-5D (0.84, 0.80, 0.74), and SF-36 PCS (44.2, 36.5, 32.6, all p<0.001). Higher preop mASD-FI scores predicted inferior postoperative scores for ODI (R2=0.193), SRS (R2=0.132), EQ-5D (R2=0.156) and SF-36 (R2=0.198). Controlling for complication incidence, baseline mASD-FI score still predicted postop scores for ODI, SRS, EQ-5D, and SF-36 (all p<0.001). Frailty also predicted higher odds of revision surgery (1.6 [1.1-2.5]) and complication (2.2 [1.5-3.2]), including infection (2.1 [1.1-3.9]), wound (2.0 [1.3-3.0]), and implant-related (2.2 [1.4-3.5]) complications. Severe frailty was associated with even greater odds of revision (2.0 [1.1-3.4]) and complication (2.8 [1.5-5.0]), including infection (2.5 [1.3-5.0]) and radiographic (2.3 [1.4-3.8]) complications. Operative treatment was associated with significant pre- to postop changes in frailty (7.2+/-5.0 to 4.9+/-4.4, p<0.001).
CONCLUSION(S): Greater preoperative frailty, as assessed by mASD-FI score, was associated with significantly greater LOS and inferior postoperative health-related quality of life across multiple outcomes assessment instruments. Frailty status was associated with increased odds of reoperation, complication, and infection. Severely frail patients showed the greatest risk of experiencing an adverse event. These results suggest the mASD-FI may have utility as a preoperative risk assessment tool. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): ASD patients (scoliosis>=20degree, SVA>=5cm, PT>=25degree, or TK >=60degree) with available mASD-FI scores and HRQL data at pre- and 2-years postop intervals were included. Patients were stratified by mASD-FI score using published cutoffs: not frail (<7), frail (7-12), severely frail (>12). Analysis of variance (ANOVA) assessed differences in demographics, surgical factors, and HRQL across frailty groups. Linear regression assessed the relationship between mASD-FI score and postop clinical outcomes (LOS, HRQL scores). Binary logistic regression assessed the relationship between frailty category and odds of complication or reoperation (results presented: odds ratio [95% confidence interval]).
RESULT(S): A total of 509 ASD patients were included (59+/-14yrs, 79%F, BMI: 27.7+/-6.0 kg/m2). The overall cohort presented with moderate baseline deformity: SVA (83.7mm+/-71), PT (12.7degree+/-10.8), PI-LL (43.1degree+/-21.1). Mean preop mASD-FI score was 7.2+/-5.0, and breakdown by frailty category was: not frail (50.3%), frail (34.0%), severely frail (15.7%). Preop age, BMI, and Charlson Comorbidity Index score all increased across increasing frailty categories (all p<0.001); however, fusion length (p=0.247) and rates of osteotomy (p=0.731) did not. At baseline, increasing frailty was associated with inferior ODI, EQ-5D, SRS-22r, SF-36 PCS, and NRS Back and Leg pain scores (all p<0.001). Following surgery, length of stay increased with increasing frailty category (6.9 days, 7.9 days, 9.6 days, p<0.001). Complication rates increased with frailty (57.6%, 64.4%, 78.7%, p<0.001). Increasing frailty was also associated with inferior postoperative outcomes for ODI (19.9, 31.8, 41.2), SRS (3.9, 3.6, 3.2), EQ-5D (0.84, 0.80, 0.74), and SF-36 PCS (44.2, 36.5, 32.6, all p<0.001). Higher preop mASD-FI scores predicted inferior postoperative scores for ODI (R2=0.193), SRS (R2=0.132), EQ-5D (R2=0.156) and SF-36 (R2=0.198). Controlling for complication incidence, baseline mASD-FI score still predicted postop scores for ODI, SRS, EQ-5D, and SF-36 (all p<0.001). Frailty also predicted higher odds of revision surgery (1.6 [1.1-2.5]) and complication (2.2 [1.5-3.2]), including infection (2.1 [1.1-3.9]), wound (2.0 [1.3-3.0]), and implant-related (2.2 [1.4-3.5]) complications. Severe frailty was associated with even greater odds of revision (2.0 [1.1-3.4]) and complication (2.8 [1.5-5.0]), including infection (2.5 [1.3-5.0]) and radiographic (2.3 [1.4-3.8]) complications. Operative treatment was associated with significant pre- to postop changes in frailty (7.2+/-5.0 to 4.9+/-4.4, p<0.001).
CONCLUSION(S): Greater preoperative frailty, as assessed by mASD-FI score, was associated with significantly greater LOS and inferior postoperative health-related quality of life across multiple outcomes assessment instruments. Frailty status was associated with increased odds of reoperation, complication, and infection. Severely frail patients showed the greatest risk of experiencing an adverse event. These results suggest the mASD-FI may have utility as a preoperative risk assessment tool. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747426
ISSN: 1878-1632
CID: 4597192
25. The collective influence of lumbopelvic mismatch and proportional shape on clinical outcomes and proximal junctional kyphosis following adult spinal deformity corrective surgery [Meeting Abstract]
BACKGROUND CONTEXT: The age-adjusted alignment ideal alignment was proposed in order reduce the occurrence of proximal junctional kyphosis (PJK) in an adult spinal deformity (ASD) population. The normative postoperative age ideal value for the mismatch between pelvic incidence and lumbar lordosis (PI-LL) has yet to be related to the global alignment and proportion (GAP) score postop proportionality. PURPOSE: To assess the impact of normative age-adjusted PI-LL and proportionality via GAP score on postoperative patient-reported outcomes. STUDY DESIGN/SETTING: Retrospective review of single-surgeon adult spinal deformity (ASD) database PATIENT SAMPLE: 140 ASD patients. OUTCOME MEASURES: Health-related quality-of-life (HRQLs); SRS-22r; PJK.
METHOD(S): ASD patients with baseline (BL) and 2-year postoperative (2Y) radiographic and HRQL data were included. Age-adjusted correction groups generated at postoperative follow-up for actual alignment compared to age-adjusted values for PI-LL-adjusted ideal values (matched, overcorrected, undercorrected). GAP Score in the literature includes the four parameters, and an age factor to formulate a sagittal plane score out of 13 (proportional, moderately disproportional [MD], severely disproportional [SD]). GAP improvement scores were noted as less at 2Y compared to BL. Patients were grouped by age-adjusted and 2Y GAP results: Match PI-LL/Proportional GAP, Match PI-LL/Disproportional GAP, Unmatch PI-LL/Proportional GAP, Unmatch PI-LL/Disproportional GAP. Means comparison and chi-squared ANOVA analyses assessed the outcomes between age-adjusted and GAP groups.
RESULT(S): Included: 140 ASD patients (55.5+/-16.4 years, 81% female, 25.2+/-4.7kg/m2). At BL, mean sacral slope: 30.7degree, pelvic tilt: 23degree, pelvic incidence: 53.5degree, PI-LL: 13.3degree, SVA: 61.6 mm, and L1-S1: 40.4degree. BL GAP proportionality: 17.8% proportional, 27.1% MD, 55% SD. PI-LL by baseline GAP proportionality groups: -6.4degree Proportional, -4.6degree MD, 26.8degree SD, p<0.001. Baseline ODI increased significantly with GAP proportionality: 27.3 Proportional, 32.3 MD, 37.4 SD, p=0.050. Assessment of 2Y age-adjusted PI-LL alignment found that 20.3% of patients Matched, 45.1% Overcorrected, and 34.6% Undercorrected. By 2Y GAP results, 32.3% were proportional, 38.5% MD, 29.5% SD (40.5% of patients improved, while 48.5% remained the same, and 11.1% deteriorated in their GAP proportionality). Categorized by the PI-LL age-adjusted/GAP groups: 2.3% Match PI-LL/Proportional GAP, 13.1% Match PI-LL/Disproportional GAP, 30% Unmatch PI-LL/Proportional GAP, 54.6% Unmatch PI-LL/Disproportional GAP. Patients who Unmatched PI-LL/Disproportional in GAP had significantly worse postoperative SRS-Pain scores (1.80 vs 3.53-3.86), SRS-Appearance (3.30 vs 3.69-4.29) and SRS-22 Total scores (2.84 vs 3.80-4.12), all p<0.050. Unmatch PI-LL/Disproportional patients developed PJK at a significantly higher rate by 6-months (66.7% vs 11.8-15.4%), p<0.050. Outcomes were not different between Match PI-LL/Disproportional GAP and Unmatch PI-LL/Proportional GAP groups.
CONCLUSION(S): Collectively over or undercorrecting in age-adjusted mismatch pelvic incidence and lumbar lordosis and becoming disproportional in spinal shape at 2 years led to increased postoperative proximal junctional kyphosis and significantly worse patient-reported outcomes. Surgeons should be wary of the double mal-correction when utilizing these complex realignment schemas. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): ASD patients with baseline (BL) and 2-year postoperative (2Y) radiographic and HRQL data were included. Age-adjusted correction groups generated at postoperative follow-up for actual alignment compared to age-adjusted values for PI-LL-adjusted ideal values (matched, overcorrected, undercorrected). GAP Score in the literature includes the four parameters, and an age factor to formulate a sagittal plane score out of 13 (proportional, moderately disproportional [MD], severely disproportional [SD]). GAP improvement scores were noted as less at 2Y compared to BL. Patients were grouped by age-adjusted and 2Y GAP results: Match PI-LL/Proportional GAP, Match PI-LL/Disproportional GAP, Unmatch PI-LL/Proportional GAP, Unmatch PI-LL/Disproportional GAP. Means comparison and chi-squared ANOVA analyses assessed the outcomes between age-adjusted and GAP groups.
RESULT(S): Included: 140 ASD patients (55.5+/-16.4 years, 81% female, 25.2+/-4.7kg/m2). At BL, mean sacral slope: 30.7degree, pelvic tilt: 23degree, pelvic incidence: 53.5degree, PI-LL: 13.3degree, SVA: 61.6 mm, and L1-S1: 40.4degree. BL GAP proportionality: 17.8% proportional, 27.1% MD, 55% SD. PI-LL by baseline GAP proportionality groups: -6.4degree Proportional, -4.6degree MD, 26.8degree SD, p<0.001. Baseline ODI increased significantly with GAP proportionality: 27.3 Proportional, 32.3 MD, 37.4 SD, p=0.050. Assessment of 2Y age-adjusted PI-LL alignment found that 20.3% of patients Matched, 45.1% Overcorrected, and 34.6% Undercorrected. By 2Y GAP results, 32.3% were proportional, 38.5% MD, 29.5% SD (40.5% of patients improved, while 48.5% remained the same, and 11.1% deteriorated in their GAP proportionality). Categorized by the PI-LL age-adjusted/GAP groups: 2.3% Match PI-LL/Proportional GAP, 13.1% Match PI-LL/Disproportional GAP, 30% Unmatch PI-LL/Proportional GAP, 54.6% Unmatch PI-LL/Disproportional GAP. Patients who Unmatched PI-LL/Disproportional in GAP had significantly worse postoperative SRS-Pain scores (1.80 vs 3.53-3.86), SRS-Appearance (3.30 vs 3.69-4.29) and SRS-22 Total scores (2.84 vs 3.80-4.12), all p<0.050. Unmatch PI-LL/Disproportional patients developed PJK at a significantly higher rate by 6-months (66.7% vs 11.8-15.4%), p<0.050. Outcomes were not different between Match PI-LL/Disproportional GAP and Unmatch PI-LL/Proportional GAP groups.
CONCLUSION(S): Collectively over or undercorrecting in age-adjusted mismatch pelvic incidence and lumbar lordosis and becoming disproportional in spinal shape at 2 years led to increased postoperative proximal junctional kyphosis and significantly worse patient-reported outcomes. Surgeons should be wary of the double mal-correction when utilizing these complex realignment schemas. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747100
ISSN: 1878-1632
CID: 4597812
P34. Evaluating the impact of multiple sclerosis on two-year postoperative outcomes following ACDF for cervical degenerative pathology: a propensity score-matched analysis [Meeting Abstract]
BACKGROUND CONTEXT: The impact of neuromuscular disorders such as multiple sclerosis (MS) on outcomes following anterior cervical discectomy and fusion (ACDF) is underreported. PURPOSE: Identify the impact of MS on two-year (2Y) postoperative complications and revisions following 2-3-level ACDF for cervical radiculopathy (CR) or myelopathy (CM). STUDY DESIGN/SETTING: Retrospective review of the New York State Statewide Planning and Research Cooperative System (SPARCS) database. PATIENT SAMPLE: Patients undergoing 2-3 level ACDF for CR/CM. OUTCOME MEASURES: Two-year postoperative complications and reoperations.
METHOD(S): Patients undergoing 2-3 level ACDF for CR/CM were identified from SPARCS. Patients with a baseline diagnosis of MS were also identified. Patients with infectious/traumatic/neoplastic were excluded. The remaining patients were 1:1 propensity score-matched (MS to no-MS) for age, sex, race, Deyo index and compared for rates of 2Y postoperative complications and reoperations. Logistic regression models were utilized to determine significant predictors of these outcomes.
RESULT(S): A total of 302 total patients were identified (MS, n=151; non-MS, n=151). MS patients were more frequently female (72.8% vs 27.2%, p<0.001). Age was comparable (50.1 vs 50.1 years, p=0.225). MS patients incurred higher charges for their surgical visit ($41,029 vs $31,654) and higher LOS (2.8 vs 2.2 days), both p<=0.016. They experienced higher rates of deep vein thrombosis (DVT) (3.3% vs 0%, p=0.02), with similar overall medical (19.2% vs 21.2%), surgical (7.9% vs 10.6%), and total complications (21.9% vs 25.8%), all p>0.05. MS patients had similar rates of 2Y revisions (6.6% vs 5.3%, p=0.627). MS was not associated with medical, surgical, or overall complications or revisions at minimum 2Y follow-up.
CONCLUSION(S): Despite differences in demographics and higher rates of postoperative DVT, MS patients experienced comparable postoperative course with respect to other individual and overall complications and revisions following 2-3-level CF for degenerative spinal pathologies. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): Patients undergoing 2-3 level ACDF for CR/CM were identified from SPARCS. Patients with a baseline diagnosis of MS were also identified. Patients with infectious/traumatic/neoplastic were excluded. The remaining patients were 1:1 propensity score-matched (MS to no-MS) for age, sex, race, Deyo index and compared for rates of 2Y postoperative complications and reoperations. Logistic regression models were utilized to determine significant predictors of these outcomes.
RESULT(S): A total of 302 total patients were identified (MS, n=151; non-MS, n=151). MS patients were more frequently female (72.8% vs 27.2%, p<0.001). Age was comparable (50.1 vs 50.1 years, p=0.225). MS patients incurred higher charges for their surgical visit ($41,029 vs $31,654) and higher LOS (2.8 vs 2.2 days), both p<=0.016. They experienced higher rates of deep vein thrombosis (DVT) (3.3% vs 0%, p=0.02), with similar overall medical (19.2% vs 21.2%), surgical (7.9% vs 10.6%), and total complications (21.9% vs 25.8%), all p>0.05. MS patients had similar rates of 2Y revisions (6.6% vs 5.3%, p=0.627). MS was not associated with medical, surgical, or overall complications or revisions at minimum 2Y follow-up.
CONCLUSION(S): Despite differences in demographics and higher rates of postoperative DVT, MS patients experienced comparable postoperative course with respect to other individual and overall complications and revisions following 2-3-level CF for degenerative spinal pathologies. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747163
ISSN: 1878-1632
CID: 4597742
P33. Complication rates following Chiari malformation surgical management for Arnold-Chiari type I based on surgical variables: a national perspective [Meeting Abstract]
BACKGROUND CONTEXT: Chiari malformations (CM) are congenital or acquired hind brain anomalies with resultant cerebellar tonsillar herniation through the foramen magnum. Chiari I malformation consists of herniation of the cerebellar tonsils into the foramen magnum thus crowding the craniocervcial junction. Surgical management is variable among these type 1 patients(pts) based on their presenting symptoms. PURPOSE: Identify complication rates following CM surgery. STUDY DESIGN/SETTING: Retrospective cohort study of (Kids' Inpatient Database) KID. PATIENT SAMPLE: Chiari Malformation Type I. OUTCOME MEASURES: Complication rates, fusion, decompression, duroplasty, laminectomy, LOS, Readmission.
METHOD(S): The KID database was queried for diagnoses of operative Chiari Malformation from 2003-2012 by ICD-9 codes (348.4). Differences in preoperative demographics (age/BMI) and perioperative complication rates between patient cohorts were assessed using Pearson's chi-squared tests and T-tests when necessary. Binary logistic regression were utilized to find significant factors associated with complication rate. Decision tree analysis was utilized for continuous variables predictive of complication rate. Certain surgical procedures were analyzed for their relationship with post-operative outcomes.
RESULT(S): A total of 13,812 CM-1 patients were isolated (10.12 yrs, 0.62 CCI). Of these pts, 8.2% (1,128) received a complication. From 2003 to 2012, the rate of complications for CM-1 pts decreased significantly (9.6%-5.1%) along with surgical rate (33.3%-28.6%), despite the increase in CM diagnosis (36.3%-42.3%; all p<0.05). CM-1 pts who had a complication were younger (9.73+/-6.8 yrs vs 10.2+/-6.3 yrs) and had a lower invasiveness score (0.35+/-1.0 vs 0.41+/-1.0), however; they had a larger CCI (1.10+/-1.6 vs 0.6+/-1.3) than those who did not have a complication (all p<0.05). The most prevalent comorbidities for these pts were cerebrovascular (16.67%), malignancy (11.6%), pulmonary (9.6%), and renal (7.1%; all p<0.05). CM-1 pts who experienced complications had a concurrent diagnosis of syringomyelia (7.1%) and also Scoliosis (3.2%; all p<0.05). CM-1 pts who did not have a complication had a greater surgical rate than those that had a complication (76.4% vs 23.6% p<0.05). Having an interbody instrument, having an invasiveness score>4.25 and receiving a fusion greater than 4 levels were all significant factors associated with receiving a complication postoperatively (p<0.05). The most common complication was nervous system related (2.8%), anemia (2.4%), and acute respiratory distress (2.1%). CM-1 pts that underwent a fusion (3.4% vs 2.1%) had greater complication rates as well as those that underwent a craniotomy (23.2% vs 19.1%; all p<0.05). However, CM-1 pts who underwent a decompression had lower postop complications (21.3% vs 28.9%; all p<0.05). A total of 13,812 CM-1 patients isolated (10.12 yrs, 0.62 CCI). Of these pts, 8.2% (1,128) received a complication. From 2003 to 2012, the rate of complications for CM-1 pts decreased significantly (9.6%-5.1%) along with surgical rate (33.3%-28.6%), despite the increase in CM diagnosis (36.3%-42.3%; all p<0.05). CM-1 pts who had a complication were younger (9.73+/-6.8yrs vs 10.2+/-6.3yrs) and had a lower invasiveness score (0.35+/-1.0 vs 0.41+/-1.0), however; they had a larger CCI (1.10+/-1.6 vs 0.6+/-1.3) than those who did not have a complication (all p<0.05). The most prevalent comorbidities for these pts were cerebrovascular (16.67%), malignancy (11.6%), pulmonary (9.6%), and renal (7.1%; all p<0.05). CM-1 pts who experienced complications had a concurrent diagnosis of syringomyelia (7.1%) and also Scoliosis (3.2%; all p<0.05). CM-1 pts who did not have a complication had a greater surgical rate than those that had a complication (76.4% vs 23.6% p<0.05). Having an interbody instrument, having an invasiveness score>4.25 and receiving a fusion greater than 4 levels were all significant factors associated with receiving a complication postoperatively (p<0.05). The most common complication was nervous system related (2.8%), anemia (2.4%), and acute respiratory distress (2.1%). CM-1 pts that underwent a fusion (3.4% vs 2.1%) had greater complication rates as well as those that underwent a craniotomy (23.2% vs 19.1%; all p<0.05). However, CM-1 pts that underwent a decompression had lower postop complications (21.3% vs 28.9%; all p<0.05).
CONCLUSION(S): Treatment of Chiari malformation has been identified to have improved from 2003 to 2012 with increased identification of diagnosis and decreased complications. Chiari patients undergoing fusions and craniotomies are at a greater risk of postoperative complications especially when the instrumented fusions are performed on >4 levels. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): The KID database was queried for diagnoses of operative Chiari Malformation from 2003-2012 by ICD-9 codes (348.4). Differences in preoperative demographics (age/BMI) and perioperative complication rates between patient cohorts were assessed using Pearson's chi-squared tests and T-tests when necessary. Binary logistic regression were utilized to find significant factors associated with complication rate. Decision tree analysis was utilized for continuous variables predictive of complication rate. Certain surgical procedures were analyzed for their relationship with post-operative outcomes.
RESULT(S): A total of 13,812 CM-1 patients were isolated (10.12 yrs, 0.62 CCI). Of these pts, 8.2% (1,128) received a complication. From 2003 to 2012, the rate of complications for CM-1 pts decreased significantly (9.6%-5.1%) along with surgical rate (33.3%-28.6%), despite the increase in CM diagnosis (36.3%-42.3%; all p<0.05). CM-1 pts who had a complication were younger (9.73+/-6.8 yrs vs 10.2+/-6.3 yrs) and had a lower invasiveness score (0.35+/-1.0 vs 0.41+/-1.0), however; they had a larger CCI (1.10+/-1.6 vs 0.6+/-1.3) than those who did not have a complication (all p<0.05). The most prevalent comorbidities for these pts were cerebrovascular (16.67%), malignancy (11.6%), pulmonary (9.6%), and renal (7.1%; all p<0.05). CM-1 pts who experienced complications had a concurrent diagnosis of syringomyelia (7.1%) and also Scoliosis (3.2%; all p<0.05). CM-1 pts who did not have a complication had a greater surgical rate than those that had a complication (76.4% vs 23.6% p<0.05). Having an interbody instrument, having an invasiveness score>4.25 and receiving a fusion greater than 4 levels were all significant factors associated with receiving a complication postoperatively (p<0.05). The most common complication was nervous system related (2.8%), anemia (2.4%), and acute respiratory distress (2.1%). CM-1 pts that underwent a fusion (3.4% vs 2.1%) had greater complication rates as well as those that underwent a craniotomy (23.2% vs 19.1%; all p<0.05). However, CM-1 pts who underwent a decompression had lower postop complications (21.3% vs 28.9%; all p<0.05). A total of 13,812 CM-1 patients isolated (10.12 yrs, 0.62 CCI). Of these pts, 8.2% (1,128) received a complication. From 2003 to 2012, the rate of complications for CM-1 pts decreased significantly (9.6%-5.1%) along with surgical rate (33.3%-28.6%), despite the increase in CM diagnosis (36.3%-42.3%; all p<0.05). CM-1 pts who had a complication were younger (9.73+/-6.8yrs vs 10.2+/-6.3yrs) and had a lower invasiveness score (0.35+/-1.0 vs 0.41+/-1.0), however; they had a larger CCI (1.10+/-1.6 vs 0.6+/-1.3) than those who did not have a complication (all p<0.05). The most prevalent comorbidities for these pts were cerebrovascular (16.67%), malignancy (11.6%), pulmonary (9.6%), and renal (7.1%; all p<0.05). CM-1 pts who experienced complications had a concurrent diagnosis of syringomyelia (7.1%) and also Scoliosis (3.2%; all p<0.05). CM-1 pts who did not have a complication had a greater surgical rate than those that had a complication (76.4% vs 23.6% p<0.05). Having an interbody instrument, having an invasiveness score>4.25 and receiving a fusion greater than 4 levels were all significant factors associated with receiving a complication postoperatively (p<0.05). The most common complication was nervous system related (2.8%), anemia (2.4%), and acute respiratory distress (2.1%). CM-1 pts that underwent a fusion (3.4% vs 2.1%) had greater complication rates as well as those that underwent a craniotomy (23.2% vs 19.1%; all p<0.05). However, CM-1 pts that underwent a decompression had lower postop complications (21.3% vs 28.9%; all p<0.05).
CONCLUSION(S): Treatment of Chiari malformation has been identified to have improved from 2003 to 2012 with increased identification of diagnosis and decreased complications. Chiari patients undergoing fusions and craniotomies are at a greater risk of postoperative complications especially when the instrumented fusions are performed on >4 levels. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747164
ISSN: 1878-1632
CID: 4597732
209. Patient-specific cervical deformity corrections with consideration of associated risk: establishment of risk benefit thresholds for invasiveness based on deformity and frailty severity [Meeting Abstract]
BACKGROUND CONTEXT: Cervical deformity (CD) severity has been linked to poor quality of life and severe neck pain. However, little is known of the relationship between surgical invasiveness accounting for cervical deformity severity and frailty status. PURPOSE: Investigate the outcomes of CD surgery by invasiveness, frailty status and baseline degree of deformity. STUDY DESIGN/SETTING: Retrospective cohort study. PATIENT SAMPLE: Ninety-six CD patients. OUTCOME MEASURES: HRQL measurements: NDI, EQ5D, mJOA.
METHOD(S): Inclusion criteria was defined as operative CD patients (C2-C7 Cobb>10degreeor CK>10degree, cSVA>4cm or CBVA>25degree) >18yr with follow up (1-year) radiographic and HRQL scores, NDI, mJOA and EQ5D. Patients were stratified by severity of deformity by TS-CL, categorized by the new-mJOA based modifiers: Low/Mod <45degree (Low-Mod); Severe >45degree(Sev). Frailty scores were calculated based upon the modified CD frailty index by Passias et. Al and categorized into severely frail (SF) >=0.5 and not SF (N-SF)<0.5. Patients were categorized by their frailty and deformity status (Low-Mod/N-SF; Low-Mod/SF; Sev/N-SF; Sev/SF). Logistic regression analysis assessed the relationship between increasing invasiveness and outcomes (DJK, complications). Within the significant frailty/deformity risk groups, decision tree analysis assessed thresholds for an invasiveness severity cut-off point, below which experiencing a reoperation, complication, DJK occurrence and poor mJOA were higher.
RESULT(S): Ninety-six CD patients met inclusion criteria (62.2+/-10.2 years, 66% female, 28.4+/-7.4 kg/m2). By approach: 19.8% anterior-only, 47.9% posterior-only, 32.3% combined (levels fused: 7.7+/-3.9). By deformity severity: 23.7% Low, 40.9% Moderate, 34.4% Severe, while frailty assessment placed 32.3% in N-SF and 67.7% SF. This categorized the patients into deformity/frailty groups as follows: 19.8% Low-Mod/N-SF(19), 13.5%(13) Sev/N-SF, 44.8%(43) Low-Mod/SF, 21.9%(21) Sev/SF. Logistic regression analysis found a significant relationship between increasing deformity severity and occurrence of severe postop DJK(1.053 [1.016-1.093], p= 0.005), complications(1.045 [1.012 - 1.080], p=0.007), revision by 1-year(1.059 [1.000-1.122], p= 0.049). Additionally, increasing invasiveness and occurrence of severe DJK (1.030 [1.007-1.054], p= 0.024) and revision (1.026 [1.008 - 1.044], p=0.005). Invasiveness increased with deformity and frailty severity: 53.6 Low-Mod/N-SF, 81.4 Sev/N-SF, 56.4 Low-Mod/SF, 79.8 Sev/SF; p=0.002. After defining a favorable outcome as no occurrence of severe DJK, no major complications and no revisions, and 1Y mJOA improvement (28.1%), invasiveness scores were compared within deformity/frailty groups between patients who met/did not meet the favorable outcome. For the NSF deformity groups, those with a favorable outcome had larger invasiveness scores (Low-Mod: 58.7 vs 48.5; Sev: 77.7 vs 89.6). For the SF deformity groups, the favorable outcome had significantly lower invasiveness scores for the Low-Mod deformity group (38.1 vs 62.9, p=0.008), while the Sev/SF deformity favorable outcome group remained larger (86.8 vs 79.4), though this was not significant. For the Low-Mod/SF group an invasiveness cutoff score of <48 where achieving a favorable outcome was 3x higher (3.08[1.2-7.9], p=0.019).
CONCLUSION(S): For SF patients, when deformity severity is low to moderate, surgeons may limit the invasiveness of their procedures in order to account for the patient's susceptibility to poor outcomes. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
METHOD(S): Inclusion criteria was defined as operative CD patients (C2-C7 Cobb>10degreeor CK>10degree, cSVA>4cm or CBVA>25degree) >18yr with follow up (1-year) radiographic and HRQL scores, NDI, mJOA and EQ5D. Patients were stratified by severity of deformity by TS-CL, categorized by the new-mJOA based modifiers: Low/Mod <45degree (Low-Mod); Severe >45degree(Sev). Frailty scores were calculated based upon the modified CD frailty index by Passias et. Al and categorized into severely frail (SF) >=0.5 and not SF (N-SF)<0.5. Patients were categorized by their frailty and deformity status (Low-Mod/N-SF; Low-Mod/SF; Sev/N-SF; Sev/SF). Logistic regression analysis assessed the relationship between increasing invasiveness and outcomes (DJK, complications). Within the significant frailty/deformity risk groups, decision tree analysis assessed thresholds for an invasiveness severity cut-off point, below which experiencing a reoperation, complication, DJK occurrence and poor mJOA were higher.
RESULT(S): Ninety-six CD patients met inclusion criteria (62.2+/-10.2 years, 66% female, 28.4+/-7.4 kg/m2). By approach: 19.8% anterior-only, 47.9% posterior-only, 32.3% combined (levels fused: 7.7+/-3.9). By deformity severity: 23.7% Low, 40.9% Moderate, 34.4% Severe, while frailty assessment placed 32.3% in N-SF and 67.7% SF. This categorized the patients into deformity/frailty groups as follows: 19.8% Low-Mod/N-SF(19), 13.5%(13) Sev/N-SF, 44.8%(43) Low-Mod/SF, 21.9%(21) Sev/SF. Logistic regression analysis found a significant relationship between increasing deformity severity and occurrence of severe postop DJK(1.053 [1.016-1.093], p= 0.005), complications(1.045 [1.012 - 1.080], p=0.007), revision by 1-year(1.059 [1.000-1.122], p= 0.049). Additionally, increasing invasiveness and occurrence of severe DJK (1.030 [1.007-1.054], p= 0.024) and revision (1.026 [1.008 - 1.044], p=0.005). Invasiveness increased with deformity and frailty severity: 53.6 Low-Mod/N-SF, 81.4 Sev/N-SF, 56.4 Low-Mod/SF, 79.8 Sev/SF; p=0.002. After defining a favorable outcome as no occurrence of severe DJK, no major complications and no revisions, and 1Y mJOA improvement (28.1%), invasiveness scores were compared within deformity/frailty groups between patients who met/did not meet the favorable outcome. For the NSF deformity groups, those with a favorable outcome had larger invasiveness scores (Low-Mod: 58.7 vs 48.5; Sev: 77.7 vs 89.6). For the SF deformity groups, the favorable outcome had significantly lower invasiveness scores for the Low-Mod deformity group (38.1 vs 62.9, p=0.008), while the Sev/SF deformity favorable outcome group remained larger (86.8 vs 79.4), though this was not significant. For the Low-Mod/SF group an invasiveness cutoff score of <48 where achieving a favorable outcome was 3x higher (3.08[1.2-7.9], p=0.019).
CONCLUSION(S): For SF patients, when deformity severity is low to moderate, surgeons may limit the invasiveness of their procedures in order to account for the patient's susceptibility to poor outcomes. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright
EMBASE:2007747231
ISSN: 1878-1632
CID: 4597562
